References
- 1. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification and management. Annual Clinical Update in Hematological Malignancies. Am J Hematol. 89; 326-337, 2014.
- 2. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(1):45-49
- 3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975; 54: 1-27.10.1097/00005792-197501000-000011090795
- 4. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis : current concepts in diagnosis and treatment. Ann Hematol 2002, 81: 677-69012483363
- 5. Valent P, Akin C and Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts, BLOOD, 16 March 2017, Volume 129, Number 11
- 6. Valent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130: 607-612.
- 7. Klion AD, Noel P, Akin C et al. Nutman Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, Vo.101, Number 12
- 8. Curtis C, Ogbogu P. Hypereosinophilic Syndrome. Clinic Rev Allerg Immunol. 2015,
- 9. Klion AD, Bochner BS, Gleich GJ et al. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol.2006; 117: 1292-1302.
- 10. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348; 1201-1214.